Beleave Inc. (CSE:BE) (OTCQX:BLEVF), one of the Canadian cannabis stocks, announced recently that its wholly-owned subsidiary, Beleave Kannabis Corp., has received authorization from Health Canada to sell cannabis oil products from January 11, 2019. Health Canada has granted an amended license with modified conditions allowing the sale of cannabis oil under the Cannabis Regulations.

Beleave Inc. Chief Science Officer Roger Ferreira said, “This license is pivotal to us meeting our goals in 2019, while driving product innovation and augmenting our research and development initiatives. Oils will continue to make up a larger part of the cannabis market, especially as we ramp up for the regulatory changes coming in 2019. Receiving our sales authorization allows us to provide a wider array of products while providing Beleave with higher margins than dried flower.”

Beleave is a fully-licensed, vertically-integrated Canadian cannabis company, cultivating high-quality cannabis flower, oil and extracts. Beleave has established technical partnerships with universities to develop pharma-grade extracts and derivatives. The Company has developed new product lines, such as cannabis-infused powder and sugar products, for 2019 in anticipation of legalization of food and beverage-based cannabis products.

On the expansion front, Beleave has established a network of medical cannabis clinics in Ontario and Quebec under the Medi- Green banner. Beleave has a majority ownership of Procannmed S.A.S to produce and distribute medical cannabis in Colombia, and to grab a foothold in Latin America. The Company also partnered with Canymed GmbH to penetrate the European medical market.

Beleave stock trades at a market capitalization of C$59.7 million with a price-to-book multiple of 3.2x.